



(51) International Patent Classification:

C12N 15/62 (2006.01) C07K 14/715 (2006.01)
C07K 14/71 (2006.01) C07K 14/705 (2006.01)

(21) International Application Number:

PCT/US2024/019690

(22) International Filing Date:

13 March 2024 (13.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/489,842 13 March 2023 (13.03.2023) US
63/495,865 13 April 2023 (13.04.2023) US
63/613,713 21 December 2023 (21.12.2023) US

(71) Applicant: **ARSENAL BIOSCIENCES, INC.** [US/US];
329 Oyster Point Blvd, South San Francisco, California
94080 (US).

(72) Inventors: **GRAY-RUPP, Levi**; c/o ARSENAL
BIOSCIENCES, INC., 329 Oyster Point Blvd, South San
Francisco, California 94080 (US). **GARDNER, Thomas**;
c/o ARSENAL BIOSCIENCES, INC., 329 Oyster Point
Blvd, South San Francisco, California 94080 (US). **YAO,**

Anzhi; c/o ARSENAL BIOSCIENCES, INC., 329 Oyster
Point Blvd, South San Francisco, California 94080 (US).

(74) Agent: **WIENS, Mayim E.** et al.; Goodwin Procter LLP,
100 Northern Avenue, IP DOCKETING DEPT./7TH FL,
Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: SYNTHETIC PATHWAY ACTIVATORS




FIG. 2B

(57) Abstract: Provided herein are novel synthetic pathway activators comprising multimerization regions, transmembrane domains, and intracellular signaling domains.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*